The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Advice for physicians when managing bispecific antibody treatment for patients with myeloma
Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, gives an overview of what community physicians need to know when treating patients with myeloma with bispecific antibodies. The main toxicities are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which are both manageable. Dr Minnema encourages physicians to start giving bispecifics to their patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
All paid to institution; Beigene, Jansen Cilag, GSK, CDR, BMS, Siemens, Binding Site.
